We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BEOVU (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
BEOVU
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
brolucizumab
Registration type
EOI
Indication
BEOVU is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD),
- Diabetic macular oedema (DME).